Why GSK’s wet-lab validation gives Chai Discovery a stronger pharmaceutical industry foothold
GSK expands Chai Discovery AI collaboration after wet-lab success. See what the binding results establish and what remains unproven.
Pharma & Biotech
Pharma & Biotech
argenx halts Phase 3 efgartigimod Sjögren’s trial after futility analysis
argenx stops the Phase 3 UNITY efgartigimod trial in Sjögren’s disease for futility despite earlier positive Phase 2 results.